Delivery Order SPE2DB25D3017-SPE2DB25FVKCE
- Not listed
- The Defense Logistics Agency (DLA) awarded a $20,272.36 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. No set-aside designation was applied...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $19,081.06 for Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKCEDelivery Order
The Defense Logistics Agency (DLA) awarded a $22,848.80 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. Dupixent is a specialized biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and other inflammatory conditions, making it a critical pharmaceutical commodity within the Defense Health Agency's medical supply chain. AmerisourceBergen's substantial IDC with DLA demonstrates the company's established capability to fulfill complex federal pharmaceutical procurement requirements across multiple therapeutic domains and geographic regions. The prime IDC serves military healthcare systems, the U.S. Coast Guard, and other federal healthcare organizations, positioning AmerisourceBergen as a key provider of specialty medications and medical supplies supporting defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.8k | 8/4/25 |